Contact Us

Advisory Board

Comprised of both anterior and posterior experts, our Industry, Medical and Scientific Advisory Board brings together leaders across ophthalmology to shape Lexitas’ strategic vision and drive growth and innovation for our customers and partners.

Meet Our Industry, Medical and Scientific Advisory Board

Carol Aune, OD

Joseph Boorady, OD

Robert Dempsey

David Eichenbaum, MD

Sherif El-Harazi, MD

Claire Gelfman, PhD

Roger Goldberg, MD

Preeya Gupta, MD

Houman Hemmati, MD

Paul Karpecki, OD

Arshad Khanani, MD

Lejla Vajzovic, MD

Hear from Our Ad Board Members

David Eichenbaum, MD
Lexitas has brought together a unique group of clinical trial stakeholders to form its advisory board—demonstrating a genuine commitment to listening, learning, and serving the needs of the ophthalmic clinical trial community. Their eagerness to tailor their approach to the evolving landscape of ophthalmology research, combined with a clear willingness to engage with and learn from this group of experienced advisors, truly sets them apart.
Carol Aune, OD
The inaugural advisory board meeting was engaging and insightful, bringing together diverse perspectives that sparked meaningful conversations. Lexitas impressed me with its thoughtful approach and clear commitment to collaboration and excellence.
Claire Gelfman, PhD
The first Lexitas advisory board meeting did not disappoint! Not only was there an assembly of leaders in the field, but we also collectively learned more about Lexitas and the clinical studies offered to the ophthalmology community, with the goal of advancing potential treatments towards approval. It was great to welcome fresh dialog from the assembled team of innovators.
Houman Hemmati, MD
By bringing together a broad range of clinical trial experts, Lexitas shows a clear focus on collaborative and informed progress in ophthalmology. I am thrilled to learn they have expanded their full-service offerings to include reading center services, allowing sponsors to have a one-stop shop for clinical trials.
Lejla Vajzovic, MD
Thank you again for a thoughtful and engaging meeting. I truly appreciated the collaborative spirit of the group and Lexitas’ clear commitment to advancing meaningful research. It was a very engaging opportunity for the retina group overall.
Paul Karpecki, OD, FAAO
The meeting was incredibly productive, well organized, novel, and likely to greatly reward Lexitas and the research community as a whole. I was impressed with the breadth of resources that Lexitas offers, the incredible retention rates of staff, and how progressive the company is, with just one example being this advisory board. I would recommend Lexitas to any company seeking to pursue FDA approval for their product.
Robert Dempsey
I greatly appreciate Lexitas’ engagement of a diverse panel of leaders across investigators, sponsors, and KOLs.  The conversation was valuable to hear from each stakeholder and their perspective on the clinical research process and how we can make improvements.
David Eichenbaum, MD
Lexitas has brought together a unique group of clinical trial stakeholders to form its advisory board—demonstrating a genuine commitment to listening, learning, and serving the needs of the ophthalmic clinical trial community. Their eagerness to tailor their approach to the evolving landscape of ophthalmology research, combined with a clear willingness to engage with and learn from this group of experienced advisors, truly sets them apart.
Carol Aune, OD
The inaugural advisory board meeting was engaging and insightful, bringing together diverse perspectives that sparked meaningful conversations. Lexitas impressed me with its thoughtful approach and clear commitment to collaboration and excellence.
Claire Gelfman, PhD
The first Lexitas advisory board meeting did not disappoint! Not only was there an assembly of leaders in the field, but we also collectively learned more about Lexitas and the clinical studies offered to the ophthalmology community, with the goal of advancing potential treatments towards approval. It was great to welcome fresh dialog from the assembled team of innovators.
Houman Hemmati, MD
By bringing together a broad range of clinical trial experts, Lexitas shows a clear focus on collaborative and informed progress in ophthalmology. I am thrilled to learn they have expanded their full-service offerings to include reading center services, allowing sponsors to have a one-stop shop for clinical trials.
Lejla Vajzovic, MD
Thank you again for a thoughtful and engaging meeting. I truly appreciated the collaborative spirit of the group and Lexitas’ clear commitment to advancing meaningful research. It was a very engaging opportunity for the retina group overall.
Paul Karpecki, OD, FAAO
The meeting was incredibly productive, well organized, novel, and likely to greatly reward Lexitas and the research community as a whole. I was impressed with the breadth of resources that Lexitas offers, the incredible retention rates of staff, and how progressive the company is, with just one example being this advisory board. I would recommend Lexitas to any company seeking to pursue FDA approval for their product.
Robert Dempsey
I greatly appreciate Lexitas’ engagement of a diverse panel of leaders across investigators, sponsors, and KOLs.  The conversation was valuable to hear from each stakeholder and their perspective on the clinical research process and how we can make improvements.
David Eichenbaum, MD
Lexitas has brought together a unique group of clinical trial stakeholders to form its advisory board—demonstrating a genuine commitment to listening, learning, and serving the needs of the ophthalmic clinical trial community. Their eagerness to tailor their approach to the evolving landscape of ophthalmology research, combined with a clear willingness to engage with and learn from this group of experienced advisors, truly sets them apart.
Carol Aune, OD
The inaugural advisory board meeting was engaging and insightful, bringing together diverse perspectives that sparked meaningful conversations. Lexitas impressed me with its thoughtful approach and clear commitment to collaboration and excellence.
Claire Gelfman, PhD
The first Lexitas advisory board meeting did not disappoint! Not only was there an assembly of leaders in the field, but we also collectively learned more about Lexitas and the clinical studies offered to the ophthalmology community, with the goal of advancing potential treatments towards approval. It was great to welcome fresh dialog from the assembled team of innovators.
Houman Hemmati, MD
By bringing together a broad range of clinical trial experts, Lexitas shows a clear focus on collaborative and informed progress in ophthalmology. I am thrilled to learn they have expanded their full-service offerings to include reading center services, allowing sponsors to have a one-stop shop for clinical trials.
Lejla Vajzovic, MD
Thank you again for a thoughtful and engaging meeting. I truly appreciated the collaborative spirit of the group and Lexitas’ clear commitment to advancing meaningful research. It was a very engaging opportunity for the retina group overall.
Paul Karpecki, OD, FAAO
The meeting was incredibly productive, well organized, novel, and likely to greatly reward Lexitas and the research community as a whole. I was impressed with the breadth of resources that Lexitas offers, the incredible retention rates of staff, and how progressive the company is, with just one example being this advisory board. I would recommend Lexitas to any company seeking to pursue FDA approval for their product.
Robert Dempsey
I greatly appreciate Lexitas’ engagement of a diverse panel of leaders across investigators, sponsors, and KOLs.  The conversation was valuable to hear from each stakeholder and their perspective on the clinical research process and how we can make improvements.